Beruflich Dokumente
Kultur Dokumente
Thursday September 7, 2017
AUPH
Aurinia Pharmaceuticals is a Canada-based clinical-stage biopharmaceutical company operating in
the field of nephrology and autoimmunity. Back in March, AUPH shot higher to the tune of 112%
in 8 days after the company reported positive results in a Phase IIb trial for its drug used for the
treatment lupus nephritis. After that initial pop, though, shares drifted back, and over the past
several months, have been in a tight range just over $6. Over the past few days, however, the
stock has started to show some signs of life, and a move out of its long base could attract attention.
As such, we’d look for an entry over $6.60, with an initial stop at $5.95.
Shark Technical Newsletter Recent Highlights
Symbol Comments
AAOI (short) Small bounce
AVEO Held 20dma
BABA Digesting
CLMT Also digesting
CSTM At highs
CTRE Developing
EXTR At highs
FENG Developing
FNSR (short) Broke down
GLYC Developing
HCCI At highs
HOLX (short) Some bounce
KEM At highs
KTOS Also at highs
MDSO (short) Forming bear flag
MDXG Back near highs
MITK Developing
MNK (short) At lows
NVCR Needs to hold $17
OLED Tried to break out but faded
OR At highs. extended
RGNX At highs
SB This too is at highs
SGMO Digesting.
TXRH (short) Broke down.
WB At highs. Extended
WGO Broke out, but faded.
IMPORTANT Disclaimer/Disclosure
This newsletter is for education purposes only and is neither investment advice nor a suggestion
to buy or sell any security at any time. Do not buy or sell the stocks discussed herein. We are
aggressive traders and will trade the stocks mentioned in a different manner than discussed
herein.
The accuracy, completeness or timeliness of the information posted here is not guaranteed. There
may be delays, omissions or inaccuracies. All readers should verify the information contained here
by other independent sources.
At the time this newsletter was published, individuals, affiliates and/or entities associated with or
related to management or owners of SharkInvesting.com and accounts managed by them held
positions in stocks discussed, mentioned and listed here. Positions may change at any time for any
reason and will be traded contrary or inconsistent with the discussion here. You should assume we
will always immediately sell long positions or close short positions as soon as possible.
DO NOT BUY OR SELL ANY STOCKS DISCUSSED HEREIN. IF YOU DO SO, YOU DO SO AT
YOUR OWN RISK. DO YOUR OWN RESEARCH AND CONSULT WITH AN INVESTMENT
ADVISOR FAMILIAR WITH YOUR SPECIFIC SITUATION. We did not provide investing advice.
Shark Investing.com and all services provided herein are for educational purposes only. Nothing
contained within this Web site should be interpreted as a recommendation to purchase, sell or
hold a security. All visitors and subscribers should always do further research before making a
final investment decision.
All subscribers must read and agree to the terms and conditions within SharkInvesting.com. Any
questions or comments may be directed to info@sharkinvesting.com. In its last quarter, the
company reported that reven
XXX
In its last quarter, the company reported that revenues increased ___% to $___ on a year over year
basis, with earnings coming in at $___ per share versus estimates of $___ on $___. The company is
expected to grow earnings by __% over the next four quarters, which gives the stock a forward PE
of _x and a PEG of __. Technically,_. We will look to start a position in this name on a move over ___,
with an initial stop at ___.